Latest filing published 07 Oct 2026 for Vaxcyte, Inc., €438k.
This profile gathers the share dealings of Elvia Cowan in Vaxcyte, Inc., where the filings describe the role as senior executive. We count 19 filings; the first trade dates from 1 March 2023 and the latest from 5 October 2026.
No open-market purchase appears, only 3 sales worth €1.7M. Other entries cover 10 share grants and 6 option exercises. 2026 to date brings no purchases and 2 sales.
The latest filing, published on 7 October 2026, reports an option exercise of €438k in Vaxcyte, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations